Skip to content

Search for:

Featured Blogs
Topics
Our Substack
Follow Us!
Contribute/Contact

Vaccine development

CD8 T cell priming occurs in two phases. In the activation phase (day 1), naïve T cells engage with dendritic cells (DC) for 24 hours, then detach, proliferate, and move deeper into the lymph node. In the selection phase (days 2-3), activated T cells regain sensitivity, re-engage with antigen-presenting cells, and receive IL-2 support from CD4 T cells. Regulatory T cells limit IL-2 availability, driving the expansion and differentiation of high-affinity CD8 T cells into effector cells.

Hidden Dance of T-Cells Reveals New Immune System Strategy Against Viruses

Photos of monkeypox in British patients, May 2022

New mRNA Vaccine Outperforms Current Options in Mpox Battle

The first PrEPVacc volunteer participant receives an injection at the launch of the launch of the PrePVacc Trial at the Masaka site of the MRC/UVRI and LSHTM Uganda Research Unit, on Tuesday 15 December 2020.

HIV Vaccine Trial Fails to Prevent Infections, Raises New Questions

Jonah Sacha, Ph.D., senior co-author of a study published today in the journal Nature Communications, says the research could lead to a universal influenza vaccine within five years.

Universal Flu Vaccine Shows Promise

Transmission electron micrograph of HIV-1 virus particles (blue) from infected H9 cells, produced in cell culture. The particles exhibit two stages of replication: the two “arcs” are immature particles budding from the plasma membrane of the cell, and the center spherical particle is a mature form in extracellular space. Image captured at the NIAID Integrated Research Facility in Fort Detrick, Maryland.

Engineered Nanoparticles Stimulate Rare Antibodies Against HIV in Animals, Advancing Vaccine Development

Kim D. Janda, PhD, the Ely R. Callaway, Jr. Professor of Chemistry at Scripps Research. Credit: Scripps Research

Scientists Develop Vaccine to Combat “Zombie Drug” Xylazine Overdose

Nurse delivers covid vaccine to woman patient's arm

Researchers develop more broadly protective coronavirus vaccine

Researcher in a fancy lab looking through a microscope

Priming, shaping and polishing: In search of a HIV vaccine

Trivalent vaccine candidate fights measles, mumps, SARS-CoV-2

Transmission electron micrograph of HIV-1 virus particles from infected H9 cells, produced in cell culture. The particles exhibit two stages of replication: the two “arcs” are immature particles budding from the plasma membrane of the cell, and the center spherical particle is a mature form in extracellular space. Image captured at the NIAID Integrated Research Facility (IRF) in Fort Detrick, Maryland.

Clinical trial of HIV vaccine begins in United States and South Africa

A colorized transmission electron micrograph of influenza A virus particles, colorized orange, isolated from a patient sample and then propagated in cell culture. NIAID

NIH clinical trial of universal flu vaccine candidate begins

Digging deeper into how vaccines work against parasitic disease

Syringe illustration. Pixabay

New vaccine may successfully target Alzheimer’s

Corona virus | Caltech

New Vaccine Technology Produces More Antibodies Against SARS-CoV-2 in Mice

Page1 Page2 Next →

Comments

Norwood johnson on Electrons in New Crystals Behave as If They Live in Four Dimensions
ScienceBlog.com on Hidden Geometry Could Finally Fix Quantum Computers
Theo Prinse on America Is Going Back to the Moon. This Time, It Plans to Stay
george w on Hidden Geometry Could Finally Fix Quantum Computers
Tom Hughes on Years of Exercise, Blood Pressure Drugs Failed to Slow Cognitive Decline in Seniors at Dementia Risk

© 2026 ScienceBlog.com | Follow our RSS / XML feed